Investigator-Initiated Research Award – W81XWH-22-TERP-IIRA – up to USD$500K over 3 years – supports studies that will make an important contribution toward research and/or patient care for a disease or condition related to toxic exposures – any phase of research from basic lab research through translational, including preclinical studies in animal models and human subjects, as well as correlative studies associated with an existing clinical trial – preliminary data required – clinical trials not allowed
Translational Research Award – W81XWH-22-TERP-TRA – up to USD$800K over 3 years or USD$1.6M over 3 years for Partnering PI option – Supports translational research that will accelerate the movement of promising ideas in toxic exposure research into clinical applications including health care products, interventions, technologies, and/or clinical practice guidelines – preliminary data required – clinical trials not allowed
Clinical Trial Award – W81XWH-22-TERP-CTA – up to USD$1.5M over 4 years or USD$2.5M over 4 years for Partnering PI option – Supports rapid implementation of clinical trials with potential for significant impact on prevention, treatment or management of symptoms, diseases, or conditions associated with or resulting from toxic exposures – projects may range from small proof-of-concept clinical trials (eg. pilot, first-in-human, phase 0) to demonstrate feasibility or inform the design of more advance trials, through large-scale trials to determine efficacy in relevant patient populations – Clinical trials may be designed to evaluate promising new products, pharmacologic agents(drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies preliminary data required – preclinical research not allowed.
- Elucidate mechanisms of how toxic exposures result in adverse effects, including, but not limited to, toxicities, malignancies, neurologic and respiratory disorders, cardiac complications, sleep disorders, immune system dysfunction, gastrointestinal issues, etc.
- Diagnose the effects of toxic exposures, understand the phenotypic/genotypic and clinical outcomes associated with short-term and long-term exposures and predict disease progression
- Predict and prevent toxic exposures by identifying strategies that can anticipate, identify, monitor and prevent Service Members and the American public from adverse effects of exposures to toxic substances.
- Develop therapeutics, treatments and strategies to minimize symptoms and disease progression associated with toxic exposures.
- Neurotoxin exposure
- Gulf War Illness and its treatment
- Airborne hazards and burn pits
- Other Military Service-Related Toxic Exposures in General, Including Prophylactic Medications, Pesticides, Organophosphates, Toxic Industrial Chemicals, Materials, Metals, and Minerals
– Letters of Intent due 3 November 2022